Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).
The test will be conducted in Israel among 50 patients who will receive CF101 over 12 weeks at four medical centers.
The results of the trial will also be sent to the US Food and Drug Administration (FDA). If CF101 is shown to be effective, Can-Fite can apply for orphan drug status, which if approved, will greatly speed up its development.
Dry eye syndrome commonly affects wearers of contact lenses, women going through menopause, and is a side effect of rheumatoid arthritis. Figures published indicate that the over six million people in the US alone suffer from dry eye syndrome, and the market for treatments is estimated at $1 billion a year.
Source: Globes [online], Israel business news - www.globes.co.il - on January 28, 2007